文献速递艾滋病与性传播感染

资源有限地区轻中度艾滋病相关卡波西肉瘤:按需与立即依托泊苷化疗联合抗逆转录病毒治疗的随机临床试验A5264/AMC-067

As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.
PubMed 文献 · Clin Infect Dis · 2018-01-01

在非洲和南美洲资源有限地区,190例开始抗逆转录病毒治疗的轻中度艾滋病相关卡波西肉瘤患者随机接受单纯抗逆转录病毒治疗(按需化疗组)或抗逆转录病毒治疗联合最多8周期口服依托泊苷(立即化疗组)。48周时两组失败、稳定和缓解比例无差异,但立即化疗组至卡波西肉瘤进展、卡波西肉瘤相关免疫重建炎症综合征和卡波西肉瘤缓解的时间更优。立即依托泊苷提供早期但非持久的临床获益,48周时与按需使用相比无临床获益,死亡率高且肿瘤缓解率低。

要点

  • 48周时按需组与立即组失败率53.8% vs 56.6%、稳定率16.3% vs 10.8%、缓解率30% vs 32.5%,无差异(P=.91)。
  • 至卡波西肉瘤进展(P=.021)、卡波西肉瘤相关免疫重建炎症综合征(P=.003)和卡波西肉瘤缓解(P=.003)的时间均有利于立即化疗组。
  • 25例死亡(13%),两组死亡率、不良事件、CD4+ T细胞变化和HIV RNA抑制在48周时相似。

核心结论

  • 在轻中度艾滋病相关卡波西肉瘤患者中,立即口服依托泊苷提供早期但非持久的临床获益,48周时与按需使用相比无临床获益,死亡率高且肿瘤缓解率低。

研究设计与样本

  • 随机临床试验(A5264/AMC-067),在非洲和南美洲纳入190例开始抗逆转录病毒治疗的化疗初治HIV-1感染轻中度卡波西肉瘤成人,随机分为按需化疗组(94例,单纯抗逆转录病毒治疗)和立即化疗组(96例,抗逆转录病毒治疗联合最多8周期口服依托泊苷)。

主要发现

  • 48周时有数据可能的163例中,按需组与立即组失败率53.8% vs 56.6%、稳定率16.3% vs 10.8%、缓解率30% vs 32.5%,无差异(P=.91)。
  • 至卡波西肉瘤进展(P=.021)、卡波西肉瘤相关免疫重建炎症综合征(P=.003)和卡波西肉瘤缓解(P=.003)的时间均有利于立即化疗组。
  • 25例死亡(13%),两组死亡率、不良事件、CD4+ T细胞变化和HIV RNA抑制在48周时相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mild-to-moderate AIDS-associated Kaposi sarcoma (KS) often responds to antiretroviral therapy (ART) alone; the role of chemotherapy is unclear. We assessed the impact of immediate vs as-needed oral etoposide (ET) among human immunodeficiency virus (HIV)-infected individuals with mild-to-moderate KS initiating ART. METHODS: Chemotherapy-naive, HIV type 1-infected adults with mild-to-moderate KS initiating ART in Africa and South America were randomized to ART (tenofovir/emtricitabine/efavirenz) alone (chemotherapy "as-needed" arm) vs ART plus up to 8 cycles of oral ET (immediate arm). Participants with KS progression on ART alone received ET as part of the as-needed strategy. Primary outcome was ordinal as follows: failure, stable, and response at 48 weeks. Secondary outcomes included time to initial KS progression, KS-associated immune reconstitution inflammatory syndrome (KS-IRIS), and KS response. RESULTS: Of 190 randomized participants (as-needed = 94, immediate = 96), the majority were men (71%) and African (93%). Failure (53.8% vs 56.6%), stable (16.3% vs 10.8%), and response (30% vs 32.5%) did not differ between arms (as-needed vs immediate) among those with week 48 data potential (N = 163, P = .91). Time to KS progression (P = .021), KS-IRIS (P = .003), and KS response (P = .003) favored the immediate arm. Twenty-five participants died (13%). Mortality, adverse events, CD4+ T-cell changes, and HIV RNA suppression were similar at 48 weeks. CONCLUSIONS: Among HIV-infected adults with mild-to-moderate KS, immediate ET provided early, nondurable clinical benefits. By 48 weeks, no clinical benefit was observed compared to use of ET as needed. Mortality was high and tumor response was low. CLINICAL TRIALS REGISTRATION: NCT01352117.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hosseinipour MC, Kang M, Krown SE, et al. As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis. 2018. PMID: 29365083. doi:10.1093/cid/ciy044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。